Infographic
Visual guide to first-line treatment selection in rheumatology
Date Published:
Register to DownloadWhen protocols are compared, early intervention correlates with better long-term outcomes, although confirmatory data are still limited. Emerging evidence indicates that digital tooling shortens time-to-decision considerably, a finding echoed by several independent groups. Recent studies suggest that integrating quantitative measures reduces subjective bias, as discussed in the accompanying commentary.
Recent studies suggest that early intervention correlates with better long-term outcomes, with meaningful differences between subgroups. Recent studies suggest that cross-disciplinary review changes the initial assessment in a sizeable minority of cases, which has direct implications for daily practice.
In multidisciplinary settings, integrating quantitative measures reduces subjective bias, pending validation in prospective studies. In multidisciplinary settings, cost considerations continue to shape adoption in smaller units, particularly in resource-constrained settings. When protocols are compared, variability between operators remains a key limitation, particularly in resource-constrained settings. Recent studies suggest that pre-analytical factors account for a large share of observed variance, particularly in resource-constrained settings. Contrary to earlier assumptions, integrating quantitative measures reduces subjective bias, pending validation in prospective studies.
Longitudinal data show that variability between operators remains a key limitation, although confirmatory data are still limited. From a workflow perspective, early intervention correlates with better long-term outcomes, and this trend is expected to continue.
References
- Okafor et al. Biomarker-guided therapy. J Rheumatology Res. 2025;22(8):291-1023.
- Meyer et al. Method validation. J Rheumatology Res. 2025;21(5):913-1025.
- Okafor et al. Assay reproducibility. J Rheumatology Res. 2025;26(8):723-1063.